Because the expression of IL-10 and CD46 is increased in patients who react to IFNb treatment compared to cells from patients who do not respond, the ability of CD4 T cells to release IL-10 is related with lower disease activity in MS [42]. The gene discussed is CD4; the disease is myeloid sarcoma.